Press Releases

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 06, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the company will participate in the RBC Capital Markets Global Healthcare Conference in New York City on Wednesday, May 15, 2024.

Date & Time: Wednesday, May 15, 4:05 PM ETFormat:... (continue reading...)

Company reports EPS of $4.14, Economic EPS of $5.37 in first quarter

• Net Income (controlling interest) of $150 million, Economic Net Income (controlling interest) of $187 million
• Economic Earnings per share increased 28% year-over-year, reflecting strong business momentum and the positive impact of our capital allocation strategy
• Issued $450 million of 40-year junior hybrid debt and repurchased approximately $150 million in common stock

WEST PALM BEACH, Fla., May 06,... (continue reading...)

• Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024
• Presented new preclinical data demonstrating potential of a MYC-targeting epigenomic controller in NSCLC at AACR 2024
• Company to present new preclinical data demonstrating durable epigenomic upregulation and other OMEGA platform capabilities at ASGCT 2024

CAMBRIDGE, Mass., May 06, 2024 ... (continue reading...)

MONTREAL, May 06, 2024 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the "Company" or "Osisko Metals") (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce an updated Mineral Resource Estimate (“MRE”) at Copper Mountain as part of the Gaspé Copper Project, located near Murdochville in the Gaspé Peninsula of Quebec.

The updated MRE (see Table 1 below) comprises an open-pit Indicated Resource of 495 million tonnes grading 0.37% CuEq,... (continue reading...)

The new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) is valid through 2035 and adds to opaganib's strong global intellectual property portfolio across multiple indications

--

U.S. Army studies suggest that opaganib may be the first host-directed molecule to show activity in vivo in Ebola virus disease, delivering a statistically significant increase in survival; separately, opaganib... (continue reading...)